BEAUTY HEALTH CO/THE (SKIN)
US88331L1089 - Common Stock
We assign a fundamental rating of 2 out of 10 to SKIN. SKIN was compared to 36 industry peers in the Personal Care Products industry. SKIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SKIN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SKIN had negative earnings in the past year.
In the past year SKIN has reported a negative cash flow from operations.
SKIN had negative earnings in 4 of the past 5 years.
In the past 5 years SKIN reported 4 times negative operating cash flow.
1.2 Ratios
SKIN has a worse Return On Assets (-4.03%) than 65.71% of its industry peers.
Looking at the Return On Equity, with a value of -47.17%, SKIN is doing worse than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.03% | ||
| ROE | -47.17% | ||
| ROIC | N/A |
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SKIN has a Gross Margin (61.43%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SKIN has declined.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SKIN has less shares outstanding
SKIN has a worse debt/assets ratio than last year.
2.2 Solvency
SKIN has an Altman-Z score of 0.20. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
SKIN has a Altman-Z score of 0.20. This is amonst the worse of the industry: SKIN underperforms 82.86% of its industry peers.
A Debt/Equity ratio of 9.23 is on the high side and indicates that SKIN has dependencies on debt financing.
SKIN's Debt to Equity ratio of 9.23 is on the low side compared to the rest of the industry. SKIN is outperformed by 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 9.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.2 |
ROIC/WACCN/A
WACC6.27%
2.3 Liquidity
A Current Ratio of 6.56 indicates that SKIN has no problem at all paying its short term obligations.
SKIN has a better Current ratio (6.56) than 94.29% of its industry peers.
SKIN has a Quick Ratio of 5.57. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN's Quick ratio of 5.57 is amongst the best of the industry. SKIN outperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.56 | ||
| Quick Ratio | 5.57 |
3. Growth
3.1 Past
SKIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -160.36%.
SKIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.94%.
The Revenue has been growing by 49.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-160.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
Revenue 1Y (TTM)-12.94%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Sales Q2Q%-19.1%
3.2 Future
The Earnings Per Share is expected to decrease by -45.50% on average over the next years. This is quite bad
Based on estimates for the next years, SKIN will show a small growth in Revenue. The Revenue will grow by 6.87% on average per year.
EPS Next Y-259.37%
EPS Next 2Y-91.06%
EPS Next 3Y-45.5%
EPS Next 5YN/A
Revenue Next Year-15.56%
Revenue Next 2Y-7.16%
Revenue Next 3Y-0.95%
Revenue Next 5Y6.87%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SKIN. In the last year negative earnings were reported.
Also next year SKIN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as SKIN's earnings are expected to decrease with -45.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-91.06%
EPS Next 3Y-45.5%
5. Dividend
5.1 Amount
SKIN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEAUTY HEALTH CO/THE
NASDAQ:SKIN (1/6/2025, 3:54:04 PM)
1.815
+0.17 (+10%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners92.88%
Inst Owner Change0%
Ins Owners8.3%
Ins Owner Change3.79%
Market Cap225.28M
Analysts51.25
Price Target2.23 (22.87%)
Short Float %6.72%
Short Ratio10.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.39%
Min EPS beat(2)20.82%
Max EPS beat(2)101.96%
EPS beat(4)4
Avg EPS beat(4)56.19%
Min EPS beat(4)9.17%
Max EPS beat(4)101.96%
EPS beat(8)7
Avg EPS beat(8)49.55%
EPS beat(12)10
Avg EPS beat(12)542.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-2.67%
Min Revenue beat(2)-9.83%
Max Revenue beat(2)4.5%
Revenue beat(4)2
Avg Revenue beat(4)0.52%
Min Revenue beat(4)-9.83%
Max Revenue beat(4)8.3%
Revenue beat(8)3
Avg Revenue beat(8)-2.65%
Revenue beat(12)7
Avg Revenue beat(12)2.09%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-437.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS2.8
BVpS0.48
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.03% | ||
| ROE | -47.17% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.43% | ||
| FCFM | N/A |
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
F-Score5
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 9.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24.49% | ||
| Cap/Sales | 2.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.56 | ||
| Quick Ratio | 5.57 | ||
| Altman-Z | 0.2 |
F-Score5
WACC6.27%
ROIC/WACCN/A
Cap/Depr(3y)59.93%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.68%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
EPS Next Y-259.37%
EPS Next 2Y-91.06%
EPS Next 3Y-45.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.94%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Sales Q2Q%-19.1%
Revenue Next Year-15.56%
Revenue Next 2Y-7.16%
Revenue Next 3Y-0.95%
Revenue Next 5Y6.87%
EBIT growth 1Y64.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.22%
EBIT Next 3Y39.84%
EBIT Next 5Y32.29%
FCF growth 1Y88.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.38%
OCF growth 3YN/A
OCF growth 5YN/A